DNA AND RNA STUDIES INTO THE NPM-ALK REARRANGEMENT IN KI-1 POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA, DIAGNOSTIC APPLICATIONS

DNA AND RNA STUDIES INTO THE NPM-ALK REARRANGEMENT IN KI-1 POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA, DIAGNOSTIC APPLICATIONS

Dettagli Bibliografici
Autori principali:	Waggott, W, Lo, Y, Bastard, C, Gatter, K, Leroux, D, Mason, D, Boultwood, J, Wainscoat, J
Natura:	Journal article
Pubblicazione:	1994

Documenti analoghi

Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma.
di: Waggott, W, et al.
Pubblicazione: (1995)

NPM-ALK gene fusion and Hodgkin's disease.
di: Waggott, W, et al.
Pubblicazione: (1997)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
di: Vijay Kumar Singh, et al.
Pubblicazione: (2019-09-01)

Identification of NPM-ALK-interacting proteins involved in the transformation of anaplastic lymphomas
di: Voena, C, et al.
Pubblicazione: (2005)

Identification of NPM-ALK-interacting proteins involved in the transformation of anaplastic lymphomas
di: Voena, C, et al.
Pubblicazione: (2005)

The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
di: Voena, C, et al.
Pubblicazione: (2007)

ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
di: Federica Lovisa, et al.
Pubblicazione: (2015-01-01)

Anaplastic Lymphoma Kinase (ALK) Rearrangement of Lung Adenocarcinoma among North Sumatera Population
di: Muhammad Yusuf Adira Putra, et al.
Pubblicazione: (2025-01-01)

Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.
di: Antoine Buetti-Dinh, et al.
Pubblicazione: (2016-01-01)

The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein
di: Pearson Joel D, et al.
Pubblicazione: (2012-06-01)

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene
di: Jo-Anne van der Krogt, et al.
Pubblicazione: (2017-09-01)

The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity
di: Paolo Bonvini, et al.
Pubblicazione: (2009-07-01)

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK+ T‐cell lymphoma
di: Wenyu Shi, et al.
Pubblicazione: (2017-09-01)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
di: Bhawana George, et al.
Pubblicazione: (2019-07-01)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
di: Naoko Shigeta, et al.
Pubblicazione: (2023-04-01)

ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions
di: Katrien Van Roosbroeck, et al.
Pubblicazione: (2010-03-01)

Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
di: Akira Satou MD, PhD, et al.
Pubblicazione: (2020-01-01)

Pathobiology of ALK-negative anaplastic large cell lymphoma
di: Stefano A. Pileri, et al.
Pubblicazione: (2011-06-01)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
di: Bhawana George, et al.
Pubblicazione: (2023-06-01)

Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.
di: Pulford, K, et al.
Pubblicazione: (2000)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
di: Yuan Wang, et al.
Pubblicazione: (2022-02-01)

MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
di: E. V. Chernyshova, et al.
Pubblicazione: (2017-01-01)

Anaplastic large cell Ki-1 lymphoma arising in bone.
di: Edwards, MS, et al.
Pubblicazione: (1993)

ALK signaling and target therapy in anaplastic large cell lymphoma
di: Fabrizio eTabbo, et al.
Pubblicazione: (2012-05-01)

Small cell pattern of ALK‐negative anaplastic large cell lymphoma with double‐hit rearrangements of DUSP22 and TP63
di: Yui Niiyama‐Uchibori, et al.
Pubblicazione: (2024-08-01)

Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant
di: Vishwanath Sathyanarayanan, et al.
Pubblicazione: (2014-11-01)

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
di: Christian Britschgi, et al.
Pubblicazione: (2020-08-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
di: Muhammad Wasi Alam, et al.
Pubblicazione: (2019-07-01)

A Case of ALK-Positive Anaplastic Large Cell Lymphoma of the Male Breast
di: Wang X, et al.
Pubblicazione: (2023-11-01)

Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma
di: Christine Damm-Welk, et al.
Pubblicazione: (2020-08-01)

<i>DUSP22</i> rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
di: Lianqun Qiu, et al.
Pubblicazione: (2022-12-01)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
di: Kazuhiro Noguchi, et al.
Pubblicazione: (2023-02-01)

<i>DUSP22</i>-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome
di: Kerry J. Savage, et al.
Pubblicazione: (2022-12-01)

ALK-Positive Anaplastic Large Cell Lymphoma: A Diagnostic Dilemma for the Otolaryngologist in a Resource Poor Setting
di: Nicholas Figaro, et al.
Pubblicazione: (2021-01-01)

Granulomatous Inflammation in a Patient with ALK-Negative Anaplastic Large Cell Lymphoma
di: Özlem Kandemir Alibakan, et al.
Pubblicazione: (2022-02-01)

Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma
di: Giulia Mura, et al.
Pubblicazione: (2023-01-01)

Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
di: Annette K. Brenner, et al.
Pubblicazione: (2021-09-01)

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
di: Ritsuko Nakai, et al.
Pubblicazione: (2019-12-01)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
di: Stefanie Kreutmair, et al.
Pubblicazione: (2022-05-01)

Pulmonary Spindle Cell Carcinoma Presenting Anaplastic Lymphoma Kinase Rearrangement
di: Kei Sonehara, et al.
Pubblicazione: (2023-09-01)